Favorable pathological response with enfortumab vedotin plus toripalimab as neoadjuvant therapy for HER2-negative muscle-invasive bladder cancer: a case report Authors: Xi Zhang, ErChang Shen, Chao Cheng, Rui Meng, Chao Liu, Qiang Shao Published: 2026 ABSTRACT PurposeTo report the efficacy and safety of enfortumab vedotin combined with toripalimab as neoadjuvant therapy in an elderly patient with muscle-invasive bladder cancer (MIBC) who sought bladder preservation.MethodsAn 83-year-old male presented with painless gross hematuria. Imaging revealed a 44 mm × 39 mm × 60 mm bladder mass, and biopsy confirmed high-grade invasive papillary urothelial carcinoma (cT2NxM0). After informed consent, the patient received three cycles of neoadjuvant therapy combining enfortumab vedotin (60 mg on days 1 and 8) with toripalimab (240 mg on days 1 and 8) in 21-day cycles.ResultsTreatment-related adverse events included hyperglycemia and rash, both managed conservatively without treatment interruption. Post-treatment MRI demonstrated marked tumor reduction, showing only bladder wall thickening. Subsequent transurethral resection of bladder tumor (TURBT) revealed chronic mucosal inflammation with histiocyte aggregation and focal cystic cystitis, with no residual carcinoma identified in the resected specimen, indicating a favorable pathological response.ConclusionIn this carefully selected elderly MIBC patient, neoadjuvant enfortumab vedotin combined with toripalimab was well tolerated and associated with marked tumor regression and a favorable pathological response on post-treatment TURBT. Bladder preservation was attempted, illustrating the feasibility of this regimen and generating a hypothesis for future investigation. Introduction Bladder cancer (BCA) is a common malignant tumor of the urinary system, ranking high in incidence and mortality among all malignancies (Sung et al. 2020; Bray et al. 2022). Muscle-invasive bladder cancer (MIBC) refers to bladder cancer that invades the bladder muscle layer, characterized by high invasiveness, rapid progression, and poor prognosis. Currently, the majority of bladder cancers are urothelial carcinomas. Surgical treatments such as radical cystectomy are currently the primary therapeutic modalities for treating MIBC (Dobruch and Oszczudłowski 2021). However, patients undergoing radical cystectomy experience decreased quality of life due to urinary diversion, leading a considerable proportion of patients to refuse surgical treatment. Therefore, bladder-sparing treatment regimens have become a current research hotspot (Lan et al. 2024). Trimodality therapy (TMT) is currently the most evidence-based bladder-preserving treatment regimen with the strongest support from clinical studies. This strategy comprises three core components: maximal transurethral resection of bladder tumor (mTURBT), systemic chemotherapy, and local radiation therapy. In recent years, immune checkpoint inhibitor (ICI) therapy has achieved promising outcomes in clinical trials for urothelial carcinoma and has gradually become a second-line or even first-line therapeutic option for advanced bladder cancer.For patients with MIBC who are ineligible for or decline radical cystectomy (RC), ICI-based regimens combined with bladder-sparing intent have emerged as a feasible clinical approach (Witjes et al. 2020). Antibody–drug conjugates (ADCs) represent another breakthrough class of targeted agents for urothelial carcinoma, and combination regimens of ADCs plus ICIs have shown synergistic antitumor activity in preliminary studies. Here, we report a case of an elderly patient with cT2NxM0 HER2-negative MIBC who was cisplatin-ineligible and received neoadjuvant therapy with enfortumab vedotin plus toripalimab for bladder-sparing purpose. After three cycles of combination treatment, the patient achieved a favorable pathological response on post-therapy TURBT, illustrating the clinical feasibility of this regimen and providing supportive evidence for further investigation. Case presentation Medical history and diagnosis An 83-year-old male patient, with no history of smoking and no family history of cancer, had a history of hypertension well-controlled with losartan potassium, and no history of diabetes or cardiovascular/cerebrovascular diseases. He presented to our hospital with painless gross hematuria lasting more than one month on November 4th, 2025. Initial physical examination upon admission showed no significant abnormalities. Urine routine examination revealed a red blood cell count of 5560/μL, white blood cell count of 237/μL, and bacterial count of 203.2/μL; serum creatinine was 77.3 μmol/L with an estimated glomerular filtration rate (eGFR) of 80 mL/min/1.73m2; baseline hemoglobin was 130 g/L, and liver function tests were within normal limits. Urinary tract MRI on November 2nd, 2025 showed a 44 mm × 39 mm × 60 mm mass in the right lateral and posterior bladder walls, highly suggestive of malignant tumor (Fig. 1). Cystoscopy and biopsy (On November 6, 2025, Fig. 2) confirmed high-grade invasive papillary urothelial carcinoma with negative HER2 expression (HER-2(0)). ECG and cardiac ultrasound showed no significant abnormalities.Fig. 1MRI of the urinary tract (kidneys, ureters, bladder) including unenhanced, contrast-enhanced, and MR urography sequences demonstrated a mass in the right lateral and posterior bladder walls (arrows), which appeared slightly hypointense on T2W-SPAIR images in coronal (A), axial (B), and sagittal (C) planes, with restricted diffusion showing hypointense signal on ADC map (D) and hyperintense signal on DWI (E)Fig. 2Histopathology of biopsy specimens showing H&E staining (A) and CK7 staining (B). Immunohistochemistry results: GATA-3(+), CK7(+), CK20(-), HER-2(0), P16(-), P53(wild-type), Ki-67(+, 40%) MRI of the urinary tract (kidneys, ureters, bladder) including unenhanced, contrast-enhanced, and MR urography sequences demonstrated a mass in the right lateral and posterior bladder walls (arrows), which appeared slightly hypointense on T2W-SPAIR images in coronal (A), axial (B), and sagittal (C) planes, with restricted diffusion showing hypointense signal on ADC map (D) and hyperintense signal on DWI (E) Histopathology of biopsy specimens showing H&E staining (A) and CK7 staining (B). Immunohistochemistry results: GATA-3(+), CK7(+), CK20(-), HER-2(0), P16(-), P53(wild-type), Ki-67(+, 40%) Baseline clinical and laboratory characteristics See Table 1 and Figs. 1, 2.Table 1Baseline clinical and laboratory characteristicsCharacteristicValueAge, years83SexMaleECOG Performance Status0Smoking historyNever smokerHistopathological diagnosisHigh-grade invasive papillary urothelial carcinomaClinical stagecT2NxM0HypertensionYes (well-controlled with losartan potassium)Baseline hemoglobin, g/L130Serum creatinine, μmol/L77.3Estimated glomerular filtration rate (eGFR), mL/min/1.73m280Alanine aminotransferase (ALT), U/L10Aspartate aminotransferase (AST), U/L13Fasting plasma glucose, mmol/L7.6Cisplatin eligibilityCisplatin-ineligible (advanced age, comorbidities)HER2 status0 (negative)Table 2Serial laboratory monitoringTime PointCorresponding Treatment StageHemoglobin(g/L)Creatinine (μmol/L)eGFR (mL/min/1.73m2)ALT (U/L)AST (U/L)Fasting Glucose (mmol/L)Nov 5, 2025Pre-treatment (Baseline)13077.38010137.6Nov 18, 2025Cycle 1 (Day 2 post first dose)12472.08214157.32Nov 25, 2025Cycle 1 (Day 9 post first dose)12066.0Not tested15148.45Dec 8, 2025Cycle 2 (Day 1)117108.0Not tested252610.14Dec 15, 2025Cycle 2 (Day 8)121112.0Not tested273312.35Dec 29, 2025Cycle 3 (Day 1)109103.0Not tested222611.98Jan 5, 2026Cycle 3 (Day 8, end of treatment)108101.0Not tested162315.75 Table 1Baseline clinical and laboratory characteristicsCharacteristicValueAge, years83SexMaleECOG Performance Status0Smoking historyNever smokerHistopathological diagnosisHigh-grade invasive papillary urothelial carcinomaClinical stagecT2NxM0HypertensionYes (well-controlled with losartan potassium)Baseline hemoglobin, g/L130Serum creatinine, μmol/L77.3Estimated glomerular filtration rate (eGFR), mL/min/1.73m280Alanine aminotransferase (ALT), U/L10Aspartate aminotransferase (AST), U/L13Fasting plasma glucose, mmol/L7.6Cisplatin eligibilityCisplatin-ineligible (advanced age, comorbidities)HER2 status0 (negative) Baseline clinical and laboratory characteristics Table 2Serial laboratory monitoringTime PointCorresponding Treatment StageHemoglobin(g/L)Creatinine (μmol/L)eGFR (mL/min/1.73m2)ALT (U/L)AST (U/L)Fasting Glucose (mmol/L)Nov 5, 2025Pre-treatment (Baseline)13077.38010137.6Nov 18, 2025Cycle 1 (Day 2 post first dose)12472.08214157.32Nov 25, 2025Cycle 1 (Day 9 post first dose)12066.0Not tested15148.45Dec 8, 2025Cycle 2 (Day 1)117108.0Not tested252610.14Dec 15, 2025Cycle 2 (Day 8)121112.0Not tested273312.35Dec 29, 2025Cycle 3 (Day 1)109103.0Not tested222611.98Jan 5, 2026Cycle 3 (Day 8, end of treatment)108101.0Not tested162315.75 Serial laboratory monitoring Treatment course Treatment regimen and administration The clinical course, including diagnostic workup, treatment schedule, adverse events, radiological reassessment, repeat TURBT, and follow-up status, is summarized in Table 3 Clinical timeline of the case.Table 3Clinical timeline of the caseDateEventDetailsEarly Oct 2025Symptom onsetPainless gross hematuriaNov 2, 2025Initial imagingMRI + MRU: bladder mass, suspected malignancyNov 4, 2025Diagnostic workupCystoscopy + biopsy; cT2NxM0, high-grade urothelial carcinoma, HER2(0); ECOG PS 1Nov 17, 2025Cycle 1, Day 1Start neoadjuvant EV 60 mg + toripalimab 240 mg (d1, d8; q21d)Nov 24, 2025Cycle 1, Day 8EV + toripalimab administeredEarly Dec 2025Adverse eventHyperglycemia (PPG 16–20 mmol/L); started metformin + acarboseDec 8, 2025Cycle 2, Day 1Treatment continuedDec 15, 2025Adverse eventRash on trunk/limbs; desloratadine + fluticasone creamDec 29, 2025Cycle 3, Day 1Resumed dexamethasone premedication; glucose controlledJan 5, 2026Cycle 3, Day 8Final dose completedJan 12, 2026Restaging MRIMarked tumor regression; focal bladder wall thickeningJan 13, 2026TURBTPathology: chronic inflammation, no residual invasive carcinomaFeb 2026–presentFollow-upBladder preservation maintained; cystoscopy + imaging q3mo Table 3Clinical timeline of the caseDateEventDetailsEarly Oct 2025Symptom onsetPainless gross hematuriaNov 2, 2025Initial imagingMRI + MRU: bladder mass, suspected malignancyNov 4, 2025Diagnostic workupCystoscopy + biopsy; cT2NxM0, high-grade urothelial carcinoma, HER2(0); ECOG PS 1Nov 17, 2025Cycle 1, Day 1Start neoadjuvant EV 60 mg + toripalimab 240 mg (d1, d8; q21d)Nov 24, 2025Cycle 1, Day 8EV + toripalimab administeredEarly Dec 2025Adverse eventHyperglycemia (PPG 16–20 mmol/L); started metformin + acarboseDec 8, 2025Cycle 2, Day 1Treatment continuedDec 15, 2025Adverse eventRash on trunk/limbs; desloratadine + fluticasone creamDec 29, 2025Cycle 3, Day 1Resumed dexamethasone premedication; glucose controlledJan 5, 2026Cycle 3, Day 8Final dose completedJan 12, 2026Restaging MRIMarked tumor regression; focal bladder wall thickeningJan 13, 2026TURBTPathology: chronic inflammation, no residual invasive carcinomaFeb 2026–presentFollow-upBladder preservation maintained; cystoscopy + imaging q3mo Clinical timeline of the case After completing the examinations, following discussion by the treatment team and multidisciplinary consultation, and referring to the 2025 EAU Bladder Cancer Guidelines (Lan et al. 2024), combined with the patient’s imaging findings, the patient was highly suspected of having muscle-invasive bladder cancer, currently staged as cT2NxM0. Therefore, the patient’s initial plan was to undergo GC protocol neoadjuvant chemotherapy followed by radical cystectomy. However, due to severe gastrointestinal reactions including frequent vomiting and loss of appetite after cisplatin use (Grade 3 according to CTCAE 5.0), the patient’s chemotherapy was discontinued.Given the patient’s advanced age and strong desire for bladder preservation, combined with the biopsy pathology results, he met the indications for perioperative treatment with enfortumab vedotin combined with immune checkpoint inhibitor therapy. After multidisciplinary discussion and informed consent, the patient received 3 cycles of neoadjuvant therapy with enfortumab vedotin (EV) plus toripalimab (21-day cycles). EV 60 mg and toripalimab 240 mg were administered intravenously on days 1 and 8 of each cycle. Intravenous dexamethasone 5 mg was given as premedication on day 1 of each cycle (as shown in Fig. 3). A total of 3 cycles of treatment were administered, specifically on November 17, 2025, November 24, 2025, December 8, 2025, December 15, 2025, December 29, 2025, and January 5, 2026. Before each treatment, the patient’s complete blood count, thyroid function, comprehensive biochemical panel, and rash conditions were examined. After completion of the third cycle of treatment, MRU was repeated and transurethral resection of bladder tumor was scheduled.Fig. 321-day treatment protocol of Enfortumab vedotin in combination with PD-1/PD-L1 inhibitors for locally advanced bladder cancer 21-day treatment protocol of Enfortumab vedotin in combination with PD-1/PD-L1 inhibitors for locally advanced bladder cancer Serial laboratory monitoring Treatment-related adverse events (CTCAE v5.0) Adverse events were graded per CTCAE v5.0. Following cycle 1, the patient developed grade 2 hyperglycemia, with postprandial glucose peaking at 20.0 mmol/L and fasting glucose at 8.4 mmol/L. Type 2 diabetes mellitus was diagnosed, and oral metformin plus acarbose were initiated. Glycemic control stabilized without treatment interruption (Table 3). After cycle 2, a grade 2 maculopapular rash appeared on the trunk and upper extremities. Topical corticosteroids and oral antihistamines resolved the eruption within one week. Dexamethasone premedication was reinstated for cycle 3. Subsequent mild rash flares remained grade 1. Glycemic parameters remained stable. Post-therapy restaging and surgical intervention Treatment was completed on January 12, 2026. Restaging MRI demonstrated marked tumor regression(Fig. 4). The anterosuperior bladder wall showed heterogeneous thickening, and the right superolateral wall exhibited focal mucosal enhancement and rigidity. Multiple non-enhancing T2-hyperintense lesions were consistent with post-treatment cystitis glandularis and diverticula. No discrete residual mass was identified.Fig. 4MRI of the urinary tract (kidneys, ureters, bladder) including unenhanced, contrast-enhanced, and MR urography sequences showed focal mucosal enhancement with slight wall rigidity in the right upper lateral bladder wall (arrows), more prominent than adjacent normal mucosa, on contrast-enhanced T2-weighted coronal (A), axial (B), and sagittal (C) images; the lesion demonstrated restricted diffusion with hypointense ADC (D) and hyperintense DWI (E) signals on axial images, with reduction in size compared to previous study MRI of the urinary tract (kidneys, ureters, bladder) including unenhanced, contrast-enhanced, and MR urography sequences showed focal mucosal enhancement with slight wall rigidity in the right upper lateral bladder wall (arrows), more prominent than adjacent normal mucosa, on contrast-enhanced T2-weighted coronal (A), axial (B), and sagittal (C) images; the lesion demonstrated restricted diffusion with hypointense ADC (D) and hyperintense DWI (E) signals on axial images, with reduction in size compared to previous study On January 13, 2026, the patient underwent transurethral resection of bladder tumor. Intraoperatively, severe trabeculation and cellules were observed in the bladder, with a small amount of neoplasm remaining on the right posterior wall. The bladder mass was completely resected down to the muscular layer, hemostasis was achieved, the bladder mass was removed, and the surgery was completed. Postoperative pathology results(as shown in Fig. 5): (bladder mass) chronic mucosal inflammation with histiocyte aggregation, focal cystic cystitis changes. Microscopic findings. Immunohistochemistry results: CK20 (umbrella cells+), P53 (wild-type), HER-2 (2+), Ki-67 (+, 5%), CD68 (histiocytes+).Fig. 5Histopathological examination of postoperative specimens with hematoxylin and eosin staining (A), CD68 immunohistochemical staining (B), and P53 immunohistochemical staining (C) Histopathological examination of postoperative specimens with hematoxylin and eosin staining (A), CD68 immunohistochemical staining (B), and P53 immunohistochemical staining (C) Discussion Radical cystectomy (RC) combined with pelvic lymphadenectomy (PLND) following neoadjuvant chemotherapy represents the well-established standard of care for resectable muscle-invasive bladder cancer (MIBC), as it maximizes the resection of tumor tissue and high-risk regional lymph nodes, reduces the risk of tumor recurrence and metastasis, and improves patient survival (Witjes et al. 2020). Nevertheless, a subset of patients undergoing RC experience a substantial decline in quality of life due to urinary diversion and infections associated with cutaneous ureterostomy (Zhang and Ke 2025). Consequently, the exploration of bladder preservation therapy (BPT) for patients with MIBC carries profound clinical significance. A pivotal focus in the implementation of BPT is whether it can achieve survival and tumor response rates comparable to those of the current RC regimen (Zlotta et al. 2023). Accumulating evidence indicates that oncological outcomes are similar between RC and trimodal therapy in carefully selected patients with MIBC. A multicenter study further suggests that BPT may be safe in patients who attain pathological complete response after neoadjuvant therapy combined with maximal transurethral resection of bladder tumor (TURBT) (Hu et al. 2022). Antibody–drug conjugates (ADCs) have emerged as a hotspot in novel therapeutic research for malignant tumors. These agents exert antitumor effects by targeting specific antigens to selectively deliver cytotoxic drugs to tumor tissues (Meng et al. 2025). Enfortumab vedotin is a novel ADC targeting Nectin-4, a cell adhesion molecule that is highly expressed in the vast majority of urothelial carcinomas, as validated by the EV101 trial, thus obviating the need for specialized target detection prior to treatment. Enfortumab vedotin exerts cytotoxicity via Nectin-4 targeting, disrupts the cellular microtubule system, and induces tumor cell apoptosis (Zschäbitz et al. 2023; Powles et al. 2024, 2025; O’Donnell et al. 2023). Toripalimab is an innovative anti-PD-1 inhibitor independently developed in China, which has demonstrated satisfactory antitumor efficacy and favorable tolerability across various malignancies. As a neoadjuvant immunotherapeutic agent, multiple clinical studies have confirmed its ability to enhance clinical response rates, with combination regimens showing superior efficacy to monotherapy (Zhang et al. 2025; Dobruch and Oszczudłowski 2021). Immunohistochemical analysis of pretreatment biopsy specimens in this patient revealed HER2 (0) expression, rendering conventional neoadjuvant regimens incorporating the HER2-targeted ADC disitamab vedotin plus PD-1 inhibitors (toripalimab or tislelizumab) ineligible for this case. Given that the EV302 trial demonstrated remarkable overall survival (OS) and progression-free survival (PFS) benefits with the combination of enfortumab vedotin and pembrolizumab, we selected this combinatorial strategy with toripalimab as the PD-1 backbone. Pembrolizumab has established its standard-of-care status in platinum-refractory advanced urothelial carcinoma based on the phase III KEYNOTE-045 randomized controlled trial, with robust evidence of OS benefit. Toripalimab was approved for the same indication in China based on data from the multicenter phase II POLARIS-03 trial (objective response rate: approximately 26.5%, median OS: 14.6 months), and cross-trial comparisons indicated favorable efficacy translation (Tang et al. 2019). Accordingly, the treatment plan was formulated as enfortumab vedotin combined with toripalimab. After three preoperative cycles of enfortumab vedotin plus toripalimab, magnetic resonance urography (MRU) showed a marked reduction in tumor size (from a broad-based 44 mm × 39 mm × 60 mm mass to mere bladder wall thickening), with complete resolution of hematuria and related symptoms. Subsequent TURBT was performed, and postoperative pathological examination revealed no residual invasive carcinoma, indicating a favorable pathological response. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0: grade 2 hyperglycemia and grade 1 maculopapular rash, both of which were well-controlled with symptomatic supportive care, without treatment discontinuation, delay, or dose modification. Serial laboratory monitoring confirmed stable hepatic and renal function, and the progressive elevation in blood glucose was consistent with the known safety profile of enfortumab vedotin and dexamethasone premedication. Several limitations warrant consideration when interpreting these findings. First, this is a single-patient observational report. Clinical staging was based on imaging and superficial biopsy, and the absence of RC and PLND precluded accurate pathological staging and lymph node assessment. Long-term oncological outcomes remain unvalidated. TURBT specimens only sampled the mucosal and superficial muscular layers, making it impossible to exclude residual microscopic disease in deep tissues or lymph nodes. Additionally, comparative efficacy against established neoadjuvant or trimodal bladder preservation regimens could not be inferred. Despite these constraints, the regimen demonstrated preliminary feasibility. Prospective trials with standardized endpoints and prolonged follow-up are warranted to define the safety, durability, and oncological adequacy of this bladder preservation approach. This single-case report suggests that neoadjuvant enfortumab vedotin combined with toripalimab is feasible, well-tolerated, and capable of achieving favorable pathological responses in elderly, HER2-negative, cisplatin-ineligible MIBC patients undergoing bladder preservation therapy. These findings provide a rationale for conducting prospective clinical trials to further evaluate this ADC plus immune checkpoint inhibitor (ICI) combination as a neoadjuvant regimen for BPT in MIBC. To date, few case reports have documented the use of enfortumab vedotin plus toripalimab in the perioperative management of locally advanced bladder cancer. Notably, during the revision of this manuscript, the patient underwent cystoscopy three months postoperatively, with no evidence of hematuria or tumor recurrence and excellent quality of life. The authors will continue to follow up on the patient’s treatment response and long-term prognosis. Conclusion This single case indicates that neoadjuvant therapy with enfortumab vedotin plus toripalimab is well tolerated and achieves a favorable pathological response in an elderly, HER2‑negative, cisplatin‑ineligible patient with cT2 muscle‑invasive bladder cancer managed with bladder‑sparing intent. These findings support the feasibility of this ADC–PD‑1 inhibitor combination as a neoadjuvant bladder‑sparing strategy and warrant further prospective clinical investigation.